We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Anti-monkeypox Drug Discovery Services Targeting Viral Polymerase
Years of experience have gained Creative Biolabs with cutting-edge knowledge and advanced technology platform, allowing us to provide stable, robust and comprehensive one-stop anti-monkeypox drug discovery services targeting viral polymerase solutions to customers all over the world.
Background of Monkeypox Virus
Monkeypox virus and other animal poxviruses belong to the family of orthopoxviruses, which are large double-stranded DNA viruses that replicate themselves in the cytoplasm of host cells. The membrane of MPXV will ablate after entering the host cell and release essential substances including viral enzymes and regulatory proteins, and replicate the viral genome with the help of viral DNA-dependent RNA/DNA polymerase, synthesizing early, intermediate and late gene products respectively. The replication of DNA and the assembly of new viruses take place in the virus factory and produce nearly 100,000 copies within 6 hours after infection.
Current Status of Anti-monkeypox Drug Discovery Targeting Viral Polymerase
Several promising monkeypox vaccines and anti-monkeypox drugs are currently in development, targeting key events and important molecules of monkeypox virus infection. A broad-spectrum anti-DNA virus acyclic nucleoside that undergoes phosphorylation in cells and selectively inhibits orthopoxvirus DNA polymerase activity and DNA synthesis process has been synthesized and used for monkeypox control. In addition, the naturally occurring adenine-based nucleosides aristeromysin and neplanocin A and their 3-deaza analogs can specifically inhibit S-adenosylhomocysteine hydrolase. Analogs synthesized based on the structures of these compounds can affect the replication process of RNA or DNA viruses. With the continuous development of molecular biology and chemical synthesis tools, more drugs have been developed for anti-monkeypox. Although some of them have not been identified with specific molecular mechanisms, their anti-monkeypox effects have been demonstrated and validated in vitro or in vivo.
Fig 1. Lesions affected by drugs after vaccination in cynomolgus monkeys. (Russo, 2019)
Technology Approaches of Anti-monkeypox Drug Discovery Targeting Viral Polymerase
Advances in molecular biology, virology and pharmacy have provided comprehensive technical and theoretical support for the screening and development of anti-monkeypox drugs. From the use of chemical synthesis databases for antiviral compound screening to antiviral activity, virus transmission testing against viral infection, enzymatic activity testing, and pharmacokinetic analysis of drug targets, many cutting-edge theories and advanced research tools have already been deployed in the development of an anti-monkeypox drug.
Fig 2. Efficacy and pharmacokinetic assay in animal models. (Grosenbach, 2018)
Creative Biolabs has been working in the field of therapeutic areas for years, and our scientists are fully confident of completing the most challenging projects. We now offer one-stop solutions for anti-monkeypox drug discovery services targeting viral polymerase and monkeypox products to our clients all over the world. No matter what stage your researches are in, we can propose a feasible and reliable solution for you. So please do not hesitate to contact us and discuss your needs.
Russo, A.T.; et al. Co-administration of tecovirimat and ACAM2000TM in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine. 2019, 10: 49.
Grosenbach, D.W.; et al. Oral Tecovirimat for the Treatment of Smallpox. The New England Journal of Medicine. 2018, 379: 44-53.